Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lupin limited - rifampicin, isoniazid, pyrazinamide - tablets - 60mg+ 30mg+ 150mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - isoniazid 50mg; pyrazinamide 300mg; rifampicin 120mg - tablet - active: isoniazid 50mg pyrazinamide 300mg rifampicin 120mg excipient: acacia aluminium hydroxide gel dried calcium stearate carmellose sodium colloidal silicon dioxide iron oxide red kaolin light magnesium oxide povidone purified talc sodium laurilsulfate sucrose titanium dioxide

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lupin limited - rifampicin, isoniazid - tablets film-coated - 150mg+ 75mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rifampicin, quantity: 300 mg - capsule, hard - excipient ingredients: purified talc; gelatin; purified water; ascorbic acid; magnesium stearate; brilliant blue fcf; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; erythrosine; lactose monohydrate - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rifampicin, quantity: 150 mg - capsule, hard - excipient ingredients: ascorbic acid; magnesium stearate; iron oxide red; colloidal anhydrous silica; purified water; lactose monohydrate; brilliant blue fcf; purified talc; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; titanium dioxide - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - isoniazid - dispersible tablets - 100

Philippines - English - FDA (Food And Drug Administration)

san marino laboratories corporation - rifampicin , pyrazinamide , isoniazid - suspension/suspension/syrup - 200mg/250mg/200mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 150 mg/100 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 300mg/150 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

royce pharma manufacturing sdn. bhd. - rifampicin -